HHT emerged from a drug screening approach as a molecule with preferential anti-leukemic effects on FLT3-expressing AML cells and displayed a synergistic action with the multi-kinase inhibitor sorafenib (Sor). The gene discussed is FLT3; the disease is acute myeloid leukemia.